Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative

European Journal of Pharmacology

Volumn 364, Issue 2-3, 1999, Pages 211-219

  Shibata, Tsutomu ^a   Matsui, Kenichi ^a   Nagao, Kaori ^a   Shinkai, Hisashi ^a   Yonemori, Fumihiko ^a   Wakitani, Korekiyo ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

Antidiabetic agent; Insulin resistance; Isoxazolidinedione; JTT 501; Non insulin dependent diabetes mellitus; PPA (peroxisome proliferator activated) receptor

Indexed keywords

ISOXAZOLIDINE DERIVATIVE; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR; PIOGLITAZONE; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; HUMAN; HUMAN CELL; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

3T3 CELLS; ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CELL DIFFERENTIATION; CHROMANS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; HYPERINSULINISM; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIC AGENTS; INSULIN; ISOXAZOLES; MALE; MICE; MICE, INBRED STRAINS; OXIDATION-REDUCTION; RATS; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 0032898052     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00832-2     Document Type: Article

References (19)

1. Burge M.R., Schmitz-Fiorentino K., Fischette C., Qualls C.R., Schade D.S. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. JAMA. 279:1998;137-143.
2. Campbell, I.W., 1990. In: Bailey, C.J., Flatt, P.R. (Eds.), Sulphonylureas and Metformin: Efficacy and Inadequacy. New Antidiabetic Drugs, Smith-Gordon.
3. DeFronzo R.A., Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 14:1991;173-194.
4. Desvergne B., Ijpenberg A., Devchand P.R., Wahli W. The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling. J. Steroid Biochem. Mol. Biol. 65:1998;65-74.
5. 2 is a ligand for the adipocyte determination factor PPARγ Cell. 83:1995;803-812.
6. Fujiwara T., Yoshioka S., Yoshioka T., Ushiyama I., Horikoshi H. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 37:1988;1549-1558.
7. Ikeda H., Taketomi S., Sugiyama Y., Shimura Y., Sohda T., Meguro K., Fujita T. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneim.-Forsch./Drug Res. 40:1990;156-162.
8. Kahn C.R. Insulin resistance: a common feature of diabetes mellitus. N. Engl. J. Med. 315:1986;252-254.
9. Keller H., Dreyer C., Medin J., Mahfoudi A., Ozato K., Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc. Natl. Acad. Sci. USA. 90:1993;2160-2164.
10. Kletzien R.F., Clarke S.D., Ulrich R.G. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol. 41:1991;393-398.
11. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 83:1995;813-819.
12. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270:1995;12953-12956.
13. Maeshiba Y., Kiyota Y., Yamashita K., Yoshimura Y., Motohashi M., Tanayama S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneim.-Forsch./Drug Res. 47:1997;29-35.
14. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
15. Shinkai H., Onogi S., Tanaka M., Shibata T., Iwao M., Wakitani K., Uchida I. Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents. J. Med. Chem. 41:1998;1927-1933.
16. Sugiyama Y., Shimura Y., Ikeda H. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneim.-Forsch./Drug Res. 40:1990;436-440.
17. Sugiyama Y., Taketomi S., Shimura Y., Ikeda H., Fujita T. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. Arzneim.-Forsch./Drug Res. 40:1990;263-267.
18. Yamazaki Y., Murakami T., Osaka T., Iino S., Mizushima Y., Inoue S. The effect of JTT-501 on serum triglycerides in obese Zucker fatty rats. Diabetologia. 40:1997;A415. Suppl. 1.
19. Zimmerman B.R. Sulfonylureas. Endocrinol. Metab. Clin. North. Am. 26:1997;511-522.